AQN Earnings

AQN reported its FY2025Q3 earnings on 2025-11-07, showcasing a revenue of 583.00M against an estimate of 599.00M, resulting in a -2.67% surprise. The EPS was 0.09, surpassing the expected 0.06 by 50% . The stock experienced a 9.09% price change on the earnings day and a 7.69% change over the next five days, reflecting market reactions to the results.

Following AQN's FY2025Q3 earnings announcement on 2025-11-07, the stock price moved by 9.09% on the day of the release. Over the subsequent five days, it saw a 7.69% change. Historically, AQN's stock price tends to shift by an average of -1.95% in the 10 days leading up to earnings and -2.23% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate AQN’s annual revenue to reach 627.00M, while the EPS is projected at 0.00. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Upward by 0.77% and EPS estimates Revise Upward by 2.59% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between AQN's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Upward by 0.77%, while EPS estimates moved Revise Upward by 2.59% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, AQN's stock price typically moves by -1.95% in the 10 days before its earnings and -2.23% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 0.00 and revenue of 627.00M.

The earnings call summary reveals mixed signals: strong net earnings growth and improved credit metrics are offset by flat EPS and unresolved billing issues. The Q&A section highlights management's focus on operational efficiency but also reveals uncertainties, particularly in regulatory challenges and divestiture timelines. The lack of a shareholder return plan and ongoing safety risks further temper enthusiasm. With a market cap of $4.1 billion, the neutral sentiment reflects balanced positives and negatives, suggesting limited short-term stock movement.